Medical Information Only: This medication is not sold on this site. The information provided is for reference purposes only. Please consult your local physician or pharmacist for treatment.

Elitek (Sanofi-Synthelabo Inc): Full Drug Profile

Medically reviewed by Dr. Otari Nergadze, Neurosurgeon | Updated: January 2026

Elitek (Sanofi-Synthelabo Inc) - General Information

Elitek (Sanofi-Synthelabo Inc) is a recombinant urate-oxidase enzyme produced by a genetically modified Saccharomyces cerevisiae strain. The cDNA coding for rasburicase was cloned from a strain of Aspergillus flavus.

 

Pharmacology of Elitek (Sanofi-Synthelabo Inc)

Drugs used to treat lympohoid leukemia, non-Hodgkin's lymphoma and acute myelogenous leukemia often lead to the accumulation of toxic plasma levels of purine metabolites (i.e. uric acid). The injection of rasburicase reduces levels of uric acid and mitigates the toxic effects of chemotherapy induced tumor lysis.

 

Additional information about Elitek (Sanofi-Synthelabo Inc)

Elitek (Sanofi-Synthelabo Inc) Indication: For treatment of hyperuricemia, reduces elevated plasma uric acid levels (from chemotherapy) Mechanism Of Action: Elitek (Sanofi-Synthelabo Inc) catalyzes enzymatic oxidation of uric acid into an inactive and soluble metabolite (allantoin). Drug Interactions: Not Available Food Interactions: Not Available Generic Name: Rasburicase Synonyms: Urate oxidase; Uricase Drug Category: Antihyperuricemic Agents Drug Type: Biotech; Approved Other Brand Names containing Rasburicase: Elitek (Sanofi-Synthelabo Inc); Absorption: Not Available Toxicity (Overdose): Not Available Protein Binding: Not Available Biotransformation: Not Available Half Life: 18 hours Dosage Forms of Elitek (Sanofi-Synthelabo Inc): Powder, for solution Intravenous Chemical IUPAC Name: Aspergilus urate oxidase Chemical Formula: C1521H2381N417O461S7 Rasburicase on Wikipedia: https://en.wikipedia.org/wiki/Rasburicase Organisms Affected: Humans and other mammals